Mehrul Hasnain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mehrul Hasnain has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
W. Victor R. Vieweg
Virginia Commonwealth University
9 shared publicationsAnanda K. Pandurangi
4 shared publicationsAnand Deshmukh
2 shared publicationsAnand K. Pandurangi
Department of Psychiatry, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond
2 shared publications- Anand K. Pandurangi
Virginia Commonwealth University
2 shared publications Antony Fernandez
Department of Psychiatry, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond
2 shared publications
Latest Publications
- Open Access
- 5 October 2016
- Published by Elsevier in The Lancet Psychiatry
- Vol. 3 (11) , 1003-1005
Schizophrenia and metabolic dysregulation: shared roots?
- 5 October 2016
- Published by Elsevier in The Lancet Psychiatry
- Vol. 3 (11) , 1003-1005
Open AccessSchizophrenia and metabolic dysregulation: shared roots?
- 1 June 2015
- Published by Oxford University Press (OUP)
- p. 1083-1111
Psychiatric Care of the Patient with Heart Disease
- 1 June 2015
- Published by Oxford University Press (OUP)
- p. 1083-1111
Psychiatric Care of the Patient with Heart Disease
- 29 August 2014
- Published by Springer Nature in CNS Drugs
- Vol. 28 (10) , 887-920
QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review
We comprehensively reviewed published literature to determine whether it supported the link between corrected QT (QTc) interval prolongation and torsade de pointes (TdP) for the 11 second-generation antipsychotics and seven second-generation antidepressants commonly implicated in these complications. Using PubMed and EMBASE, we identified four thorough QT studies (one each for iloperidone, ziprasidone, citalopram, and escitalopram), 40 studies specifically designed to assess QTc interval prolongation or TdP, 58 publications based on data from efficacy and safety trials, 18 toxicology studies, and 102 case reports. Thorough QT studies, QTc prolongation-specific studies, and studies based on efficacy and safety trials did not link drug-associated QTc interval prolongation with TdP. They only showed that the drugs reviewed caused varying degrees of QTc interval prolongation, and even that information was not clear and consistent enough to stratify individual drugs for this risk. The few toxicology studies provided valuable information but their findings are pertinent only to situations of drug overdose. Case reports were most informative about the drug–QTc interval prolongation–TdP link. At least one additional well established risk factor for QTc prolongation was present in 92.2 % of case reports. Of the 28 cases of TdP, six (21.4 %) experienced it with QTc interval <500 ms; 75 % of TdP cases occurred at therapeutic doses. There is little evidence that drug-associated QTc interval prolongation by itself is sufficient to predict TdP. Future research needs to improve its precision and broaden its scope to better understand the factors that facilitate or attenuate progression of drug-associated QTc interval prolongation to TdP.
- 29 August 2014
- Published by Springer Nature in CNS Drugs
- Vol. 28 (10) , 887-920
QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review
We comprehensively reviewed published literature to determine whether it supported the link between corrected QT (QTc) interval prolongation and torsade de pointes (TdP) for the 11 second-generation antipsychotics and seven second-generation antidepressants commonly implicated in these complications. Using PubMed and EMBASE, we identified four thorough QT studies (one each for iloperidone, ziprasidone, citalopram, and escitalopram), 40 studies specifically designed to assess QTc interval prolongation or TdP, 58 publications based on data from efficacy and safety trials, 18 toxicology studies, and 102 case reports. Thorough QT studies, QTc prolongation-specific studies, and studies based on efficacy and safety trials did not link drug-associated QTc interval prolongation with TdP. They only showed that the drugs reviewed caused varying degrees of QTc interval prolongation, and even that information was not clear and consistent enough to stratify individual drugs for this risk. The few toxicology studies provided valuable information but their findings are pertinent only to situations of drug overdose. Case reports were most informative about the drug–QTc interval prolongation–TdP link. At least one additional well established risk factor for QTc prolongation was present in 92.2 % of case reports. Of the 28 cases of TdP, six (21.4 %) experienced it with QTc interval <500 ms; 75 % of TdP cases occurred at therapeutic doses. There is little evidence that drug-associated QTc interval prolongation by itself is sufficient to predict TdP. Future research needs to improve its precision and broaden its scope to better understand the factors that facilitate or attenuate progression of drug-associated QTc interval prolongation to TdP.
- 14 March 2014
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 20 (38) , 6007-6013
Possible Role of Vascular Risk Factors in Alzheimer's Disease and Vascular Dementia
The contribution of vascular risk factors to Alzheimer-vascular spectrum dementias is increasingly being recognized. We provide an overview of recent literature on this subject. Overweight and obesity as well as underweight during midlife predict cognitive decline and dementia later in life. Hypertension during midlife is also associated with dementia later in life and the association is stronger for untreated hypertension. Calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin-1 receptor-blockers may be particularly beneficial in diminishing the risk of dementia associated with hypertension. Studies have fairly consistently shown that type 2 diabetes is a risk factor for dementia. Episodes of hypoglycemia add to this risk. Regular physical exercise during any point in the lifespan protects against cognitive decline and dementia. Most benefit is realized with physical exercise during early and midlife. Dyslipidemia also increases the risk of dementia but the findings are less consistent. Findings on the possible benefit of lipid-lowering agents (statins) are conflicting. Earlier studies identified smoking as protective of dementia but recent better designed studies have consistently shown that smoking increases the risk of dementia. The association of vascular risk factors with dementia is more robust for vascular dementia than Alzheimer’s disease. Heterogeneity of studies and lack of trials specifically designed to assess cognition as an endpoint make firm conclusions difficult. But considering the expected global burden of dementia and projected attributable risk of vascular risk factors to it, there is sufficient evidence to promote vascular risk factor reduction strategies as dementia prevention interventions.
- 14 March 2014
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 20 (38) , 6007-6013
Possible Role of Vascular Risk Factors in Alzheimer's Disease and Vascular Dementia
The contribution of vascular risk factors to Alzheimer-vascular spectrum dementias is increasingly being recognized. We provide an overview of recent literature on this subject. Overweight and obesity as well as underweight during midlife predict cognitive decline and dementia later in life. Hypertension during midlife is also associated with dementia later in life and the association is stronger for untreated hypertension. Calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin-1 receptor-blockers may be particularly beneficial in diminishing the risk of dementia associated with hypertension. Studies have fairly consistently shown that type 2 diabetes is a risk factor for dementia. Episodes of hypoglycemia add to this risk. Regular physical exercise during any point in the lifespan protects against cognitive decline and dementia. Most benefit is realized with physical exercise during early and midlife. Dyslipidemia also increases the risk of dementia but the findings are less consistent. Findings on the possible benefit of lipid-lowering agents (statins) are conflicting. Earlier studies identified smoking as protective of dementia but recent better designed studies have consistently shown that smoking increases the risk of dementia. The association of vascular risk factors with dementia is more robust for vascular dementia than Alzheimer’s disease. Heterogeneity of studies and lack of trials specifically designed to assess cognition as an endpoint make firm conclusions difficult. But considering the expected global burden of dementia and projected attributable risk of vascular risk factors to it, there is sufficient evidence to promote vascular risk factor reduction strategies as dementia prevention interventions.
- 1 February 2014
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 34 (1) , 3-6
Quetiapine and the Need for a Thorough QT/QTc Study
- 1 February 2014
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 34 (1) , 3-6
Quetiapine and the Need for a Thorough QT/QTc Study
- 5 November 2013
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 4 (3) , 130-138
Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports
Recently, both the manufacturer of quetiapine and the US Food and Drug Administration warned healthcare providers and patients about quetiapine-induced QTc interval prolongation and torsade de pointes ( TdP) when using this drug within the approved labeling. We reviewed the case-report literature and found 12 case reports of QTc interval prolongation in the setting of quetiapine administration. There were no cases of quetiapine-induced TdP or sudden cardiac death (SCD) among patients using quetiapine appropriately and free of additional risk factors for QTc interval prolongation and TdP. Among the 12 case reports risk factors included female sex (nine cases), coadministration of a drug associated with QTc interval prolongation (eight cases), hypokalemia or hypomagnesemia (six cases) quetiapine overdose (five cases), cardiac problems (four cases), and coadministration of cytochrome P450 3A4 inhibitors (two cases). There were four cases of TdP. As drug-induced TdP is a rare event, prospective studies to evaluate the risk factors associated with QTc prolongation and TdP are difficult to design, would be very costly, and would require very large samples to capture TdP rather than its surrogate markers. Furthermore, conventional statistical methods may not apply to studies of TdP, which is rare and an ‘outlier’ manifestation of QTc prolongation. We urge drug manufacturers and regulatory agencies to periodically publish full case reports of psychotropic drug-induced QTc interval prolongation, TdP, and SCD so that clinicians and investigators may better understand the clinical implications of prescribing such drugs as quetiapine.
- 5 November 2013
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 4 (3) , 130-138
Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports
Recently, both the manufacturer of quetiapine and the US Food and Drug Administration warned healthcare providers and patients about quetiapine-induced QTc interval prolongation and torsade de pointes ( TdP) when using this drug within the approved labeling. We reviewed the case-report literature and found 12 case reports of QTc interval prolongation in the setting of quetiapine administration. There were no cases of quetiapine-induced TdP or sudden cardiac death (SCD) among patients using quetiapine appropriately and free of additional risk factors for QTc interval prolongation and TdP. Among the 12 case reports risk factors included female sex (nine cases), coadministration of a drug associated with QTc interval prolongation (eight cases), hypokalemia or hypomagnesemia (six cases) quetiapine overdose (five cases), cardiac problems (four cases), and coadministration of cytochrome P450 3A4 inhibitors (two cases). There were four cases of TdP. As drug-induced TdP is a rare event, prospective studies to evaluate the risk factors associated with QTc prolongation and TdP are difficult to design, would be very costly, and would require very large samples to capture TdP rather than its surrogate markers. Furthermore, conventional statistical methods may not apply to studies of TdP, which is rare and an ‘outlier’ manifestation of QTc prolongation. We urge drug manufacturers and regulatory agencies to periodically publish full case reports of psychotropic drug-induced QTc interval prolongation, TdP, and SCD so that clinicians and investigators may better understand the clinical implications of prescribing such drugs as quetiapine.
- 9 May 2013
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 128 (6) , 488-489
Antipsychotic drug‐treated patients best suited for metformin therapy
- 9 May 2013
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 128 (6) , 488-489
Antipsychotic drug‐treated patients best suited for metformin therapy
- 1 July 2012
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 124 (4) , 154-167
Weight Gain and Glucose Dysregulation with Second-Generation Antipsychotics and Antidepressants: A Review for Primary Care Physicians
Second–generation antipsychotics (SGAPs) and second–generation antidepressants (SGADs) have multiple US Food and Drug Administration–approved indications and are frequently prescribed by primary care physicians. We review the relative potential of these drugs to cause weight gain and glucose dysregulation, and offer clinical guidance to minimize and manage this risk. Among SGAPs, clozapine and olanzapine have a high risk for causing weight gain and glucose dysregulation; iloperidone, paliperidone, quetiapine, and risperidone have a medium risk; and aripiprazole, asenapine, lurasidone, and ziprasidone have a low risk. Young, drug–naïve patients are particularly vulnerable to weight gain associated with SGAPs. With the exception of clozapine, SGAPs have modest differences in their efficacy; however, their side effect profiles may influence selection. Using SGAPs with high metabolic liability conservatively and limiting their off–label use are important means to minimize risk. Patients should be scre...
- 1 July 2012
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 124 (4) , 154-167
Weight Gain and Glucose Dysregulation with Second-Generation Antipsychotics and Antidepressants: A Review for Primary Care Physicians
Second–generation antipsychotics (SGAPs) and second–generation antidepressants (SGADs) have multiple US Food and Drug Administration–approved indications and are frequently prescribed by primary care physicians. We review the relative potential of these drugs to cause weight gain and glucose dysregulation, and offer clinical guidance to minimize and manage this risk. Among SGAPs, clozapine and olanzapine have a high risk for causing weight gain and glucose dysregulation; iloperidone, paliperidone, quetiapine, and risperidone have a medium risk; and aripiprazole, asenapine, lurasidone, and ziprasidone have a low risk. Young, drug–naïve patients are particularly vulnerable to weight gain associated with SGAPs. With the exception of clozapine, SGAPs have modest differences in their efficacy; however, their side effect profiles may influence selection. Using SGAPs with high metabolic liability conservatively and limiting their off–label use are important means to minimize risk. Patients should be scre...
- 1 July 2011
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 71 (1) , 6-12
Depression screening in patients with coronary heart disease: A critical evaluation of the AHA guidelines
- 1 July 2011
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 71 (1) , 6-12
Depression screening in patients with coronary heart disease: A critical evaluation of the AHA guidelines
- 12 May 2011
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 123 (6) , 409-410
Do we truly appreciate how difficult it is for patients with schizophrenia to adapt a healthy lifestyle?
- 12 May 2011
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 123 (6) , 409-410
Do we truly appreciate how difficult it is for patients with schizophrenia to adapt a healthy lifestyle?